These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17511614)

  • 1. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders.
    Kehne JH
    CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):163-82. PubMed ID: 17511614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.
    Kehne JH; Cain CK
    Pharmacol Ther; 2010 Dec; 128(3):460-87. PubMed ID: 20826181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
    Valdez GR
    CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.
    Kehne J; De Lombaert S
    Curr Drug Targets CNS Neurol Disord; 2002 Oct; 1(5):467-93. PubMed ID: 12769601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
    Griebel G; Simiand J; Stemmelin J; Gal CS; Steinberg R
    Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):191-200. PubMed ID: 12769799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neurobiology of depression: inroads to treatment and new drug discovery.
    Nemeroff CB; Vale WW
    J Clin Psychiatry; 2005; 66 Suppl 7():5-13. PubMed ID: 16124836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRF receptors as a potential target in the development of novel pharmacotherapies for depression.
    Valdez GR
    Curr Pharm Des; 2009; 15(14):1587-94. PubMed ID: 19442175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.
    Hauger RL; Risbrough V; Brauns O; Dautzenberg FM
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):453-79. PubMed ID: 16918397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F; Ising M
    Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin in health and disease with a focus on affective disorders.
    Zelena D
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
    Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
    Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR; Heinrichs SC; Grigoriadis DE
    Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in corticotropin-releasing factor-1 antagonist development.
    Zorrilla EP; Koob GF
    Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of corticotropin-releasing factor in depression and anxiety disorders.
    Arborelius L; Owens MJ; Plotsky PM; Nemeroff CB
    J Endocrinol; 1999 Jan; 160(1):1-12. PubMed ID: 9854171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics.
    Chen C
    Curr Med Chem; 2006; 13(11):1261-82. PubMed ID: 16712469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
    Taché Y; Martinez V; Million M; Maillot C
    Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link.
    Stahl SM
    J Clin Psychiatry; 1997; 58 Suppl 8():20-6. PubMed ID: 9236732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRF1 receptors as a therapeutic target for irritable bowel syndrome.
    Martinez V; Taché Y
    Curr Pharm Des; 2006; 12(31):4071-88. PubMed ID: 17100612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.